Support the work of AORTIC by becoming an AORTIC 2019 sponsor and showcasing your commitment to the promotion of cancer care and control in Africa. There are sponsorship opportunities at various price points, and all of the opportunities come with significant benefits.
Create a bespoke package that suits your organisation’s goals and budget by selecting from the wide range of opportunities. Depending on the total value of your sponsored items, you may reach a sponsorship recognition tier that qualifies you for additional benefits. For example, if your total is USD 100 000, you will be recognised as a Platinum Sponsor and enjoy tier benefits over and above the benefits linked with each sponsorship item you have selected.
The mission of the American Cancer Society (ACS) is to save lives, celebrate lives, and lead the fight for a world without cancer. With more than 100 years of experience and leadership, we are a global force, fighting all cancers on all fronts, across the US and around the globe.
With the help of millions of supporters, we launch breakthrough research, create empowering resources for people to outsmart cancer, enable communities to support those affected, and convene powerful activists to create awareness and impact.
ACS is proud to support the 12th International Conference on Cancer in Africa to be held in Maputo, Mozambique this November. During this year’s conference, ACS will host sessions addressing harmonised cancer treatment guidelines for Sub-Saharan Africa, safely handling and administering of chemotherapy, building capacity of civil society organisations and their role in addressing the growing cancer burden in Africa, and how patient navigation can improve patient’s access to care and cancer experience and ACS’s plans to expand patient navigation to lower-resourced settings globally.
ACS will also be hosting a special workshop on “HPV vaccination for cervical cancer prevention”. The workshop will provide a quick overview of cervical cancer and its prevention with a special focus on HPV vaccination. Participants will learn simple key messages about HPV vaccination, discuss common myths and misconceptions, and will then engage in a communication role play activity to put this learning into practice. Participants will walk away confident in their ability to communicate the basics about HPV vaccination.
ACS’s sessions at AORTIC 2019
The US National Cancer Institute (NCI) is the leading funder of cancer research worldwide. The NCI Center for Global Health collaborates with institutions and researchers in the US, Africa and globally to support cancer research-associated networks, and the dissemination of evidence to inform cancer control.
NCI is pleased to support the 12th International Conference on Cancer in Africa. The AORTIC Conference allows multidisciplinary researchers, clinicians, advocates, and policymakers to exchange information and build networks to strengthen cancer research and control in Africa.
We look forward to networking with you throughout the conference, and these NCI sessions:
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.
In Africa, Roche aims to improve every step of a patient’s journey by removing barriers to access quality healthcare—from diagnosis to treatment— because we believe patients in Africa deserve the same treatment as everyone else. We are building on our lasting commitment to business in Africa and 120 years of pioneering in healthcare to make a difference where we are needed most.
Takeda Pharmaceutical Company Limited is a global biopharmaceutical leader committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. Takeda believes access to healthcare and medicines should be universal. However, across the world, many people lack access to the services and treatment they need. Together with strategic partners across multiple sectors, we are committed to helping to strengthen healthcare systems in a sustainable way, at every stage of the patient journey.
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com.
Products and services
For Elekta, Precision Radiation Medicine means delivering globally accessible, precise and personalized radiation therapy that targets the tumor and protects the patient. Our solutions include radiotherapy, stereotactic radiosurgery, magnetic resonance radiation therapy, brachytherapy, oncology informatics, neurosurgery and Elekta Care™, our comprehensive services program designed to support healthcare professionals throughout their entire Elekta experience.
Recent product introductions, including MOSAIQ® Plaza and Elekta Unity MR-Linac, as well as continued advances to the family of HD linear accelerators and MR-guided brachytherapy, demonstrate Elekta’s continued commitment to advancing oncology care. Features in the new solutions include higher personalization, improved workflows, better precision and more intelligence through automation as well as through analytics and supporting through evidence-driven decision support.
Every year, close to 1.5 million patients are treated with an Elekta solutions. 6,000 hospitals use Elekta products and services in more than 120 countries across the globe.
Varian is the world’s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Visitwww.varian.com for more information.